Why Is Plus Therapeutics Stock Moving Higher On Thursday?

Plus Therapeutics Inc PSTV has entered into an agreement with RadioMedix Inc to produce the company's radiopharmaceuticals commercially.
"This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM)," said Marc Hedrick, President & CEO of Plus Therapeutics.
186RNL is being developed to treat recurrent GBM, leptomeningeal metastases, and pediatric brain cancer.
Related Content: Recently, Plus Therapeutics presented data from a Phase 1 ReSPECT trial evaluating Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM).
Price Action: PSTV shares are up 14.2% at $2.17 during the market session on the last check Thursday.